Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

and heart rate for Empatic are similar to or more favorable than the placebo-subtracted changes observed with Contrave, and there are no signals of cardiovascular concern in the Empatic development program, reassuring results of a cardiovascular outcomes trial with Contrave will be sufficient. In addition, while the FDA reiterated the belief that the teratogenicity potential for zonisamide is very concerning, the FDA will allow Phase 3 studies of Empatic to include women of childbearing potential who have a Body Mass Index that meets the FDA definition of overweight (>27kg/m2) in the presence of at least one weight-related comorbidity. Orexigen owns worldwide rights to Empatic. Prior to initiating Phase 3 studies of Empatic, the Company plans to seek a collaboration partner to help fund further clinical development and, if approved, commercialization.

Conference Call Today at 5 p.m. Eastern Time (2:00 p.m. Pacific Time) The Orexigen management team will host a teleconference and webcast to discuss the second quarter 2013 financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 35366685. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... LifeScienceIndustryResearch.com announces having a ... Global and China Lysine Industry to its research ... the deep research report in this field. For ... including definition, classification specifications, application, industry chain structure, ... Europe , Japan , ...
(Date:4/17/2015)... -- CVS Health Corporation (NYSE: CVS ) will ... 2015, at 8:30 a.m. (EDT) with analysts and investors ... An audio webcast of the conference call will be ... CVS Health website for all interested parties. To access ... be archived and available on the web site for ...
(Date:4/17/2015)... 2015  Trovagene, Inc., (NASDAQ:  TROV) a developer ... data presented at the 2015 European Lung Cancer ... Monitoring ℠ (PCM) platform outperformed tissue biopsy ... T790M mutations in metastatic lung cancer patients. ... Mutation in Urinary Circulating Tumor DNA from Metastatic ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
... MYL ) today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... The company was the first to have filed a substantially ... for Clopidogrel Tablets, 300 mg, and was awarded 180 days ...
... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... the development, assembly, marketing and sale of medical devices ... will present at the CFA 2012 Cross-Continental Summit on ... Hotel in Shanghai on May 18, 2012. ...
Cached Medicine Technology:Mylan Launches Generic Version of Plavix® Tablets 2Dehaier Medical to Present at the CFA 2012 Cross-Continental Summit on Investment in Shanghai 2
(Date:4/17/2015)... April 17, 2015 Baptist Health and ... signed a partnership agreement designed to transform oncology care ... institutions have agreed to create a joint cancer program ... and translational research. Baptist MD Anderson Cancer Center is ... a single destination for highly coordinated, multidisciplinary cancer care ...
(Date:4/17/2015)... 2015 Scientists from the Icahn ... of U.S. and Venezuelan researchers, have discovered the ... among an isolated tribe of Yanomami Amerindians in ... in the Yanomami, previously unexposed to antibiotics or ... that of people living in industrialized countries, and ...
(Date:4/17/2015)... TX (PRWEB) April 17, 2015 Connie ... specialist and functional medicine advocate with 30 years of ... will be adding another level of service for her ... her website of 10 recommended wellness books with a ... When asked to explain her interest in providing this ...
(Date:4/17/2015)... Compare-autoinsurance.org has released a new blog ... auto insurance quotes . , The online environment ... their cars. Drivers should always compare multiple car insurance ... market is a competitive one, which means that customers ... , It is now possible to compare online car ...
(Date:4/17/2015)... April 17, 2015 Oxytocin ... posterior pituitary and thought to help mothers bond to ... To further substantiate this, new studies performed, at NYU ... Nature, and reported by Medical News Today on April ... influence over maternal social behavior. The study reveals that, ...
Breaking Medicine News(10 mins):Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2Health News:The Best Auto Insurance Quotes Are Available Online! 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 3
... Team of researchers at the University of NSW in Sydney have ... ,This is a 3D motion cue which is dynamic //half-occlusion. ... motion. ,It appears as a free access ... ,Building on principles of binocular geometry established by Leonardo ...
... study initiated by U.S. researchers on the medical histories ... were either blind or suffered weak eyesight, revealed that ... caused Vitamin A deficiency, leading to poor eyesight or ... issue of the British Journal of Ophthalmology. ...
... study has brought out the immense health benefits of ... behavioral attributes, even before //they arrive into the world. ... significantly lowered with consumption of fish oil by the ... double, because it directly impacts the unborn baby as ...
... depression, anxiety, suicidal thoughts and other mental health problems ... image than others - a study of adolescents in ... Dyl of Brown Medical School in Providence, Rhode Island ... body shape and weight are likely to be suffer ...
... cancer can talk to doctor through their beloved ones, especially ... ,The head of the Prostate Cancer Foundation, Leslie ... are daughters, wives and partners whom can realize their role ... prostrate cancer. ,More than 27,000 men were ...
... on the rise have brought the world to stand and ... future generations //. The American College of Cardiology (ACC) and ... pays attention to valvular heart disease. ,Valve ... flow between the left atrium and the left ventricle, or ...
Cached Medicine News:
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
... is the anterior alternative to the Ray TFC ... the same 70% fenestrations as Ray TFC. The ... in the formation of new bone. As with ... load sharing between the device and the spine.* ...
... Ray Threaded Fusion Cage is a proven interbody* ... IDE). This device is a hollow threaded cylinder ... this contact the device promotes spinal fusion by ... Ray TFC is indicated for use with autogenous ...
... Donor Screening: The Procleix System ... safety to the nation's blood supply. It ... target capture, and a unique nucleic acid ... HIV-1/HCV Assay can simultaneously detect the presence ...
Medicine Products: